Ipsen S.A.

ENXTPA:IPN 株式レポート

時価総額：€13.4b

Ipsen 配当と自社株買い

配当金 基準チェック /06

Ipsenは配当を支払う会社で、現在の利回りは0.86%です。次の支払い日は 5th June, 2026で、権利落ち日は3rd June, 2026 。

主要情報

0.9%

配当利回り

0.5%

バイバック利回り

総株主利回り1.4%
将来の配当利回り1.0%
配当成長5.1%
次回配当支払日05 Jun 26
配当落ち日03 Jun 26
一株当たり配当金n/a
配当性向26%

最近の配当と自社株買いの更新

Recent updates

ナラティブの更新 • May 17

IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential

Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.
ナラティブの更新 • Apr 24

IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential

Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.
ナラティブの更新 • Apr 10

IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook

Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.
ナラティブの更新 • Mar 27

IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside

The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
ナラティブの更新 • Mar 13

IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside

The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.
ナラティブの更新 • Feb 27

IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential

The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.
ナラティブの更新 • Feb 12

IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook

Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.
ナラティブの更新 • Jan 29

IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook

Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.
ナラティブの更新 • Jan 15

IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook

Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.
ナラティブの更新 • Dec 21

IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook

Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.
ナラティブの更新 • Dec 07

IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook

Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.
ナラティブの更新 • Nov 22

IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook

Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.
ナラティブの更新 • Nov 07

IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade

Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.
分析記事 • Oct 28

Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
ナラティブの更新 • Oct 24

Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide

Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.
ナラティブの更新 • Sep 25

Pipeline Catalysts And Approvals Will Expand Global Access

Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.
分析記事 • Sep 07

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?

Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...
分析記事 • Jul 13

Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings

Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
User avatar
新しいナラティブ • Feb 23

Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025

Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.

配当金の支払いについて

今日May 26 2026配当落ち日Jun 03 2026配当支払日Jun 05 20262 days 配当落ちから次の8 days 、次の配当を受け取るために購入する。

決済の安定と成長

配当データの取得

安定した配当: IPNはFrench市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。

増加する配当: IPNはFrench市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。

配当利回り対市場

Ipsen 配当利回り対市場
IPN 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (IPN)0.9%
市場下位25% (FR)2.0%
市場トップ25% (FR)5.6%
業界平均 (Pharmaceuticals)4.6%
アナリスト予想 (IPN) (最長3年)1.0%

注目すべき配当: IPNの配当金 ( 0.86% ) はFrench市場の配当金支払者の下位 25% ( 1.95% ) と比べると目立ったものではありません。

高配当: IPNの配当金 ( 0.86% ) はFrench市場の配当金支払者の上位 25% ( 5.59% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: IPN French市場において目立った配当金を支払っていません。

株主配当金

キャッシュフローカバレッジ: IPN French市場において目立った配当金を支払っていません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 14:54
終値2026/05/25 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ipsen S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Richard SilverBarclays
Charles PitmanBarclays
Charles PitmanBarclays